Dexcom Appoints Rimma Driscoll to Board of Directors
28 Agosto 2023 - 9:30AM
Business Wire
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring, today announced the appointment of
Rimma Driscoll to its Board of Directors, effective August 24,
2023.
Ms. Driscoll is an accomplished leader with significant
experience developing, guiding and executing organic and inorganic
growth strategies for global organizations. She currently serves as
Executive Vice President and Head of Global Strategy, Commercial
and Business Development, and Global BioDevices for Zoetis, the
world’s leading animal health company and a member of the Fortune
500. In this role, Ms. Driscoll oversees the company’s global
business strategy, the execution of commercial launch plans,
external business development and integration efforts, and has
oversight for Zoetis’ Global BioDevices business. She brings to the
Dexcom Board a track record of impactful leadership across the
global healthcare, consumer and animal health industries, including
the successful completion of several transformative transactions
and key product launches.
“We are very excited to welcome Rimma to the Dexcom Board,” said
Kevin Sayer, chairman, president and CEO at Dexcom. “Her strategic
guidance at Zoetis and Procter & Gamble has been instrumental
in helping these two global organizations achieve and grow their
market leadership positions. As we continue to extend access to
Dexcom’s real-time CGM systems to more people throughout the world,
we look forward to benefiting from Rimma’s experience navigating
global commercial markets and key strategic partnerships.”
About Rimma Driscoll
Rimma Driscoll is Executive Vice President and Head of Global
Strategy, Commercial and Business Development, and Global
BioDevices for Zoetis. Prior to assuming this role as a member of
the Zoetis Executive Leadership Team in 2022, Ms. Driscoll served
as Senior Vice President and Head of Global Business Development,
Business Integrations and Strategic Alliances from 2020 to 2022,
and Vice President and Head of Global Business Development and
Strategic Alliances for Zoetis from 2016 to 2020.
Prior to her executive leadership at Zoetis, Ms. Driscoll served
in roles of increasing responsibility at Procter & Gamble from
1994 to 2016. She established and led the company’s global business
development group in Geneva, Switzerland, during her tenure as
Executive Global Head for Europe, Corporate Global Business
Development from 2012 to 2016.
In addition to her current role at Zoetis, Ms. Driscoll
currently serves as a member of the Board of Directors of Pumpkin
Insurance, a preventive care and pet insurance provider in which
Zoetis has a minority stake. She holds a bachelor’s degree in
Chemistry from Bowling Green State University and earned her MBA
from Xavier University.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit Dexcom.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230828942848/en/
Media Contact James McIntosh 619-884-2118
james.mcintosh@dexcom.com
Investor Contact Sean Christensen 858-203-6657
sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024